Summary
By virtue of their potential to selectively silence oncogenic molecules in cancer cells, antisense oligonucleotides (ASO) and small interfering RNAs (siRNAs) are powerful tools for development of tailored anti-cancer drugs. The clinical benefit of ASO/siRNA therapeutic is, however, hampered due to poor pharmacokinetics and biodistribution, and suboptimal suppression of the target in tumor tissues. Raf-1 protein serine/threonine kinase is a druggable signaling molecule in cancer therapy. Our laboratory has developed cationic liposomes for systemic delivery of raf ASO (LErafAON) and raf siRNA (LErafsiRNA) to human tumor xenografts grown in athymic mice. LErafAON is also the first ASO containing liposomal drug tested in humans. In this article, we primarily focus on a modified formulation of systemically delivered cationic liposomes containing raf antisense oligonucleotide (md-LErafAON). The cationic liposomes were prepared using dimyristoyl 1,2-diacyl-3-trimethylammonium-propane (DMTAP), phosphatidylcholine (PC), and cholesterol (CHOL). The toxicology, pharmacokinetics, biodistribution, target selectivity, and anti-tumor efficacy studies of md-LErafAON were conducted in mice. We demonstrate that md-LErafAON is the next generation of systemically delivered and well-tolerated antisense therapeutic suitable for clinical evaluation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kasid, U., Pfeifer, A., Brennan, T., Beckett, M., Weichselbaum, R.R., Dritschilo, A., and Mark, G.E. (1989) Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354–1356.
Soldatenkov, V.A., Dritschilo, A., Wang, F-H., Olah, Z., Anderson, W.B., and Kasid, U. (1997) Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Can. J. Sci. Am. 3, 13–20.
Iorns, E., Lord, C.J., Turner, N., and Ashworth, A. (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556–568.
Monia, B.P., Johnston, J.F., Geiger, T., Muller, M., and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 6, 668–675.
Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajiala, L., Saxinger, C., and Zhang, R. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 94, 2620–2625.
Marshall, J.L., Eisenberg, S.G., Johnson, M.D., Hanfelt, J., Dorr, F.A., El-Ashry, D., Oberst, M., Fuxman, Y., Holmlund, J., and Malik, S. (2004) A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 4, 268–274.
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Röhl, I., Toudjarska, I.., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., and Vornlocher, H.P. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178.
Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C.S., Jeffs, L.B., Judge, A., MacLachlan, I.., and Polisky, B. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002–1007.
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685–689.
Baigude, H., McCarroll, J., Yang, C.S., Swain, P.M., and Rana, T.M. (2007) Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 24, 237–241.
Gokhale, P.C., Soldatenkov, V., Wang, F-H., Rahman, A., Dritschilo, A., and Kasid, U.(1997) Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implications for gene therapy of radioresistant cancer. Gene Ther. 4, 1289–1299.
Gokhale, P.C., McRae, D., Monia, B.P., Bagg, A., Rahman, A., Dritschilo, A., and Kasid, U. (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 9, 191–201.
Gokhale, P.C., Zhang, C., Newsome, J., Pei, J., Ahmad, I., Rahman, A., Dritschilo, A., and Kasid, U. (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome (LErafAON). Clin. Cancer Res. 8, 3611–3621.
Mewani, R.R., Tang, W., Rahman, A., Dritschilo, A., Ahmad, I., Kasid, U.N., and Gokhale, P.C. (2004) Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int. J. Oncol. 24, 1181–1188.
Pei, J., Zhang, C., Gokhale, P.C., Rahman, A., Dritschilo, A., Ahmad, I., and Kasid, U. (2004) Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel, and gemcitabine. Anticancer Drugs 15, 243–253.
Pal, A., Ahmad, A., Khan, S., Sakabe, I., Zhang, C., Kasid, U., and Ahmad, I. (2005) Systemic delivery of RafsiRNA using cationic cardiolipin liposome silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26, 1087–1091.
Zhang, C., Pei, J., Kumar, D., Sakabe, I., Boudreau, H.E., Gokhale, P.C., and Kasid, U.N. (2007) Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. In: Target Discovery and Validation Reviews and Protocols, Vol. 2, Emerging Molecular Targets and Treatment Options (Sioud, M., ed). Humana Press, Inc. Methods Mol. Biol. 361, pp 163–185.
Heidel, J.D., Yu, Z., Liu, J.Y., Rele, S.M., Liang, Y., Zeidan, R.K., Kornbrust, D.J., and Davis, M.E. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715–5721.
Pirollo, K.F., Rait, A., Zhou, Q., Hwang, S.H., Dagata, J.A., Zon, G., Hogrefe, R.I., Palchik, G., and Chang, E.H. (2007) Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938–2943.
Palliser, D., Chowdhury, D., Wang, Q.Y., Lee, S.J., Bronson, R.T., Knipe, D.M., and Lieberman, J. (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89–94
Kasid, U. and Dritschilo, A. (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876–5884.
Kasid, U., Suy, S., Dent, P., Ray, S., Whiteside, T.L., and Sturgill, T.W. (1996) Activation of Raf by ionizing radiation. Nature 382, 813–816.
Suy, S., Anderson, W.B., Dent, P., Chang, E., and Kasid, U. (1997) Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene 15, 53–61.
Rudin, C.M., Holmlund, J., Fleming, G.F., Mani, S., Stadler, W.M., Schumm, P., Monia, B.P., Johnston, J.F., Geary, R., Yu, R.Z., Kwoh, T.J., Dorr, F.A., and Ratain, M.J. (2001) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7, 1214–1220.
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835–844.
Rudin, C.M., Marshall, J.L., Huang, C.H., Kindler, H.L., Zhang, C., Kumar, D., Gokhale, P.C., Steinberg, J., Wanaski, S., Kasid, U.N., and Ratain, M.J. (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 10, 7244–7251.
Dritschilo, A., Huang, C.H., Rudin, C.M., Marshall, J., Collins, B., Dul, J.L., Zhang, C., Kumar, D., Gokhale, P.C., Ahmad, A., Ahmad, I., Sherman, J.W., and Kasid, U.N. (2006) Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12, 1251–1259.
Boudreau, H.E., Broustas, C.G., Gokhale, P.C., Kumar, D., Mewani, R.R., Rone, J.D., Haddad, B.R., and Kasid, U. (2007) Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. Int. J. Mol. Med. 19, 29–39.
Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics, 2nd edition. Marcel Dekker, New York, pp 45–111.
Acknowledgments
We thank Dr. Lisa Portnoy, Ms. Laura Rutter-Call, Ms. Carrie Silver, and Ms. Amy Durham for technical assistance, and our colleagues and collaborators for their comments. PC-3 cells were obtained from the Tissue Culture Shared Resource, and microscopy was performed at the Microscopy Shared Resource of the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center. Mice clinical pathology and histopathology tests were performed by ANTECH Diagnostics, and data evaluated by a board-certified veterinary pathologist (Pathology Associates International). The liposomal formulation and its use presented in this study are patented (United States patent #s 6126965, 6333314, 6559129, and 7262173). The research work was supported by grants from the National Institutes of Health and NeoPharm, Inc.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Zhang, C., Newsome, J.T., Mewani, R., Pei, J., Gokhale, P.C., Kasid, U.N. (2009). Systemic Delivery and Pre-clinical Evaluation of Nanoparticles Containing Antisense Oligonucleotides and siRNAs. In: Belting, M. (eds) Macromolecular Drug Delivery. Methods in Molecular Biology, vol 480. Humana Press. https://doi.org/10.1007/978-1-59745-429-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-59745-429-2_5
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-999-4
Online ISBN: 978-1-59745-429-2
eBook Packages: Springer Protocols